| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00043426-200311000-00006 |
| P698 | PubMed publication ID | 14608193 |
| P50 | author | Alessandra Longhi | Q63499939 |
| Davide Maria Donati | Q57081200 | ||
| P2093 | author name string | Mario Mercuri | |
| Stefano Ferrari | |||
| Rodolfo Capanna | |||
| Franco Bertoni | |||
| Gaetano Bacci | |||
| Gabriella Bernini | |||
| Elisabetta Setola | |||
| Antonio Briccoli | |||
| Cristiana Forni | |||
| Michela Versari | |||
| P433 | issue | 11 | |
| P921 | main subject | chemotherapy | Q974135 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 845-853 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | Journal of Pediatric Hematology/Oncology | Q15761808 |
| P1476 | title | Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome | |
| P478 | volume | 25 |
| Q48252313 | A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. |
| Q36496709 | Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma |
| Q38506118 | Advances in emerging drugs for osteosarcoma |
| Q56996677 | Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients |
| Q55439578 | Does intensified chemotherapy increase survival outcomes of osteosarcoma patients? A meta-analysis. |
| Q54475781 | Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma? |
| Q40125470 | Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi |
| Q33557868 | Inhibition of tumors cell growth in osteosarcoma-bearing SD rats through a combination of conventional and metronomic scheduling of neoadjuvant chemotherapy |
| Q53493398 | Knee reconstruction with endoprosthesis after extra-articular and intra-articular resection of osteosarcoma. |
| Q85933731 | Letter regarding Zhang et al. entitled "Systematic review of high-dose and standard-dose chemotherapies in the treatment of primary well-differentiated osteosarcoma" |
| Q40530173 | Limb salvage surgery for osteosarcoma: Early results in Indian patients |
| Q37313880 | Metformin displays in vitro and in vivo antitumor effect against osteosarcoma |
| Q39888581 | Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma |
| Q46879986 | Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan |
| Q79274923 | Osteosarcoma Necrosis Following Chemotherapy: Innate Biology Versus Treatment-Specific |
| Q36195151 | Pediatric osteosarcoma: a 35-year experience in Slovenia |
| Q37687395 | Prognostic markers in osteosarcoma |
| Q57226639 | RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma |
| Q55395574 | Rho A Regulates Epidermal Growth Factor-Induced Human Osteosarcoma MG63 Cell Migration. |
| Q36440294 | Survival trends and long-term toxicity in pediatric patients with osteosarcoma. |
| Q38232992 | Systematic review of high-dose and standard-dose chemotherapies in the treatment of primary well-differentiated osteosarcoma |
| Q37696336 | Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance |
| Q34721714 | Targeting osteosarcoma vasculature with peptide obtained by phage display |
| Q35858388 | The efficacy of high-dose versus moderate-dose chemotherapy in treating osteosarcoma: a systematic review and meta-analysis |
| Q33367102 | The feasibility of neoadjuvant high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma: results of a phase II study |
| Q90676997 | Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma |
| Q35319234 | mTORC1 maintains the tumorigenicity of SSEA-4(+) high-grade osteosarcoma |
Search more.